Introduction
Metastasis is an involved process in which cancer cells invade new tissues and develop as secondary cancers.
Several genes, known as metastasis suppressors, have recently been identified which inhibit metastasis, and little is known regarding the mechanisms by which they act or how their expression is regulated in both normal and tumorigenic tissues (Steeg et al., 2003) . KiSS-1, is a precursor for secreted peptide ligands for the G-protein coupled receptor, hGRP54 (Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001; Stafford et al., 2002) . Microcell-mediated transfer of highly metastatic melanoma was initially used to identify KiSS-1 as a metastasis suppressor gene, as it was shown to reduce invasive and migratory properties without affecting tumorigenicity (Lee and Welch, 1997b) . Similar to that of other known metastasis suppressors, the expression of KiSS-1 is commonly found to be inversely correlated to the degree of cancer metastasis. Consequently, loss of KiSS-1 expression has been shown to be a good indicator for the progression of several types of cancers (Lee and Welch, 1997b; Sanchez-Carbayo et al., 2003; Ikeguchi et al., 2004; Masui et al., 2004; Jiang et al., 2005) . Additionally, overexpression or treatment with KiSS-1 peptide, reduces invasive and migratory properties of cancer cells in vitro (Lee and Welch, 1997a, b; Ohtaki et al., 2001; Stafford et al., 2002; Masui et al., 2004) . Several labs have shown that deletion of 6q16.3-q23 and loss of heterozygosity correlate with increased metastasis and decreased KiSS-1 expression, suggesting that KiSS-1 may be regulated by genes encoded within that region (Miele et al., 2000; Shirasaki et al., 2001) . The objective of this study was thus to identify the upstream regulator(s) of KiSS-1 which localize to chromosome 6q16.3-q23.
DRIP-130, also known as cofactor required for Sp1 transcriptional activation (CRSP3), is one of 15 subunits which compose the transcriptional cofactor complex CRSP/mediator, and is required for transcriptional activation by Sp1 Taatjes and Tjian, 2004) . Previous research suggests DRIP-130 itself acts as a metastasis suppressor, and that its expression correlates directly to the expression of other metastasis suppressors in clinical samples of melanoma, thus making DRIP-130 a likely and interesting candidate regulatory factor of KiSS-1 (Goldberg et al., 2003) . Here, we report that reintroduction of DRIP-130 in highly metastatic melanoma cells induces higher KiSS-1 expression, and that coexpression of Sp1 and DRIP-130 decreases invasive and migratory properties of metastatic melanoma cells. Furthermore, we demonstrate that KiSS-1 expression is modulated by Sp1 elements within the first 100-bp region of the KiSS-1 promoter and that targeted deletion of a single GC-rich region spanning À93 to À58 of the promoter interrupts Sp1-and DRIP-130-modulated transcriptional control of KiSS-1 expression. Therefore, our data provides a regulatory mechanism for the loss of KiSS-1 gene expression commonly seen in metastatic melanomas and correlates it with the gross loss of genetic material on human chromosome 6q16.3-q23 that leads to heightened tumor metastasis.
Results
Identification of the regulatory region of KiSS-1 promoter by Sp1 and its coactivator DRIP-130 in melanoma The full-length human KiSS-1 promoter has a high GCcontent and contains multiple putative Sp1 sites, with more than 10 overlapping putative Sp1 sites in the first 100 bases alone (see Figure 1a) . Recent evidence has revealed that the transcription factor, Sp1, requires the presence of other cofactors, including the CRSP complex, for proper assembly on Sp1-modulated promoters. . To determine whether the transcriptional effect of Sp1 on KiSS-1 expression in melanoma is modulated by the Sp1 co-activator, DRIP-130, we examined the effects of Sp1 and DRIP-130 on activation of KiSS-1 promoter using a series of KiSS-1 promoter-bearing luciferase constructs (see Figure 1a) . Luciferase assays were carried out as described previously, and normalized using b-galactosidase levels (Mitchell et al., 2006) . As shown in Figure 1b , whereas single transfections of DRIP-130 and Sp1 had no effect, co-expression of both Sp1 and DRIP-130 resulted in a six-eightfold increase in the highly metastatic melanoma cell line, WM2664 (Figure 1b) . To determine the discrete region modulating Sp1 and DRIP-130 response, luciferase assays using serial truncations of the KiSS-1 promoter sequence were performed. Nearly the same fold increase in KiSS-1 transactivation was observed using the 1000-, 150-and the 100-base pair sequence of the KiSS-1 promoter, suggesting that the region modulating KiSS-1 transactivation was located within the first 100 bases (Figure 1b) .
To examine whether the transcriptional effects of Sp1 and DRIP-130 were tissue/cell specific, we measured activation of the KiSS-1 promoter by Sp1 and DRIP-130 in four different metastatic cancer cell lines, two melanoma (WM2664 and A375SM) and two breast cancer cell lines (T47D and MDA-435). As shown Figure 1c , co-transfection of Sp1 and DRIP-130 greatly enhanced activation in metastatic melanoma cells, however, only slight activation was observed when co-transfection was done using the two highly metastatic breast cancer cell lines (Figure 1c) , suggesting that KiSS-1 transactivation by Sp1 and DRIP-130 may be tissue-specific (Figure 1c ).
KiSS-1 levels in highly metastatic melanoma correlates directly to the expression of DRIP-130 mRNA and protein To determine whether a correlation existed between the expression of KiSS-1, Sp1 and DRIP-130 in melanoma, we examined their expression in melanoma cell lines of different metastatic capacities (Figure 2a and b) . Owing to the lack of a specific and effective KiSS-1 antibody, KiSS-1 expression was quantitated using reverse transcription-polymerase chain reaction (RT-PCR) and real-time PCR, and then normalized to the expression levels of b-actin and glyceraldehyde-3-phosphate dehydrogenase, respectively in Figure 2a and b. Results showed that the more metastatic cell lines, A375SM and (Figure 2b ). Although a slight increase in Sp1 expression was seen in the SB2 line, Sp1 expression remained relatively constant, as compared to the actin loading control. To determine whether reduced expression of DRIP-130 in melanoma was responsible in part for significantly decreased KiSS-1 levels found in the more metastatic WM2664 and A375SM melanoma cell lines, Sp1 and DRIP-130 were singly transfected into these cells, which were then lysed and analysed for KiSS-1 expression using RT-PCR. As no significant increase in KiSS-1 messenger RNA (mRNA) levels was seen (results not shown), cells were then co-transfected with both Sp1 and DRIP-130. Results demonstrated that co-transfection induced KiSS-1 expression levels in melanoma ( Figure 2c , middle, co-transfected) as compared to the untransfected cells (Figure 2c, top) . This data suggests that overexpression of both Sp1 and DRIP-130 is required for increased KiSS-1 expression in metastatic melanoma cell lines.
Determination of the KiSS-1 promoter region responsive to transcriptional upregulation by DRIP-130 and Sp1
To demonstrate the importance of the first 100 bases in mediating the effects of Sp1 and DRIP-130, we measured the levels of luciferase induction by constructs driven by just the first 100 bp of the KiSS-1 promoter or by a promoter construct with targeted deletion of this region. Results showed that this 100 bp region was sufficient for the transactivation mediated by DRIP-130 and Sp1 (Figure 3a) , and that targeted deletion resulted in the loss of response to Sp1 and DRIP-130 ( Figure 3a , last three columns). Additionally, these results suggest that whereas many putative Sp1 sites are located throughout the full-length human KiSS-1 promoter, the transcriptional effects of DRIP-130 and Sp1 may be confined to the first hundred bases of the promoter. To further support the significance of Sp1 binding elements localized within the 100 bp region proximal to the KiSS-1 start site, Electrophoretic mobility shift assay (EMSA) was performed to determine whether these sites were physically capable of binding the Sp1 transcription factor. Within the first hundred base pairs of the human KiSS-1 promoter sequence, a single GC-rich region spanning À93 to À58 and consisting of approximately ten overlapping putative Sp1 elements stood out as the likely candidate for modulating DRIP-130 and Sp1 upregulation and was subsequently the first tested for Sp1 binding. WM2664 cells, which were transfected to overexpress DRIP-130 and Sp1, were lysed and incubated with a radiolabeled probe spanning fifty bases of the promoter sequence including the candidate GC-rich region. The resulting patterns of bands revealed that Sp1 formed a DNA-protein complex ( Figure 3b , lane 2). Incubation of an unlabeled probe competed for protein binding, and resulted in a reduction of DNA-protein complex and band intensity (Figure 3b, lane 3) . Only the Sp1-specific antibody was capable of super shifting the DNA-protein complex (Figure 3b , lane 5) whereas the control anti-immunoglobulin (Ig)G antibody had no effect (Figure 3b , lane 4). The negative control in which labeled probe is seen in the absence of nuclear extract is shown in Figure 3b , lane 1. EMSA results using Sp1/ Regulation of KiSS-1 expression in melanoma by Sp1 and DRIP-130 DC Mitchell et al DRIP-130 co-transfected A375SM cells showed similar results (data not shown), suggesting that direct interaction of Sp1 occurs within this short 50 bp region, specifically the 34 bases consisting entirely of overlapping Sp1 sites.
DRIP-130 and Sp1 complex co-precipitates with chromatin at GC-rich 34-bp region of KiSS-1 promoter in melanoma As DRIP-130 is known to be a component of the larger CRSP co-activator complex required for Sp1 transactivation, the ability of DRIP-130 to interact with the chromatin bound 100-bp fragment of the KiSS-1 promoter was examined. Chromatin immunoprecipitation (ChIP) analysis in which sheared DNA isolated from DRIP-130/Sp1 co-transfected WM2664 melanoma cells was immunoprecipitated overnight using antibodies specific to DRIP-130, Sp1 and IgG. primers, designed to overlap the Sp1-rich cluster between -1 and -150, were used to amplify the fragment of the immunoprecipitated chromatin (Figure 3c) . Results showed that the Sp1 antibody was able to immunoprecipitate the first 150-bp of the chromatin-bound KiSS-1 promoter (Figure 3d, lane 4) . However, anti-IgG, the negative control, did not precipitate the KiSS-1 promoter and thus did not form PCR product (Figure 3d , lane 3). Because ChIP using endogenous levels of protein were inconclusive, we chose to use lysates in which both Sp1 and DRIP-130 were overexpressed, resulting in an additive effect of DNA-protein interaction, by which we could demonstrate specific Sp1 interaction with the KiSS-1 promoter. Controls included the PCR products using both the non-immunoprecipitated input (lane 2) and a vector containing the full-length KiSS-1 promoter sequence (lane 1). Furthermore, the antibody to DRIP-130 immunoprecipitated this region of the KiSS-1 promoter (Figure 3d, lane 5) . Previous incubation of the DRIP-130-specific antibody in EMSA assays showed no conclusive DNA-protein interaction (data not shown), however, such seemingly inconsistent findings may likely result from even very small differences in the antibody or protein binding conditions in EMSA and ChIP assays. Generally, however, ChIPP assays are considered more sensitive and ChiP assays using A375SM cells were consistent with WM264 results. From our ChIP assays, we conclude that DRIP-130 exists in a protein complex that binds to the Sp1 cluster between -93 and -58 in the chromatin-bound form.
Co-transfection of metastatic melanoma cell lines with DRIP-130 and Sp1 results in reduced migratory and invasive properties in vitro KiSS-1 is known to inhibit migration and invasion when overexpressed in NIH3T3 cells and other cells (Lee and Welch, 1997b; Stafford et al., 2002) . Considering that co-transfection of both DRIP-130 and Sp1 resulted in an increase of KiSS-1 expression (Figure 2b ), functional assays measuring the degree of invasive and migratory behavior of melanoma cells were used to determine whether re-introduction of DRIP-130 and Sp1 in highly metastatic melanoma was sufficient to induce the metastatic inhibition seen with KiSS-1 overexpression. Wound-healing assays using WM2664 cells transfected with vector-only (Figure 4a 5,  respectively) to the chromatin-bound KiSS-1 promoter in WM2664 cells. Precipitation using an IgG-specific antibody was used as a negative control (lane 3), whereas, the positive control for the PCR reaction using a KiSS-1 promoter expressing construct is seen in lane 1. A portion of the chromatin-bound promoter before antibody incubation was also used as a control for the PCR reaction (lane 2).
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showed a similar amount of wound healing, whereas, Sp1-transfected cells seemed to show slightly greater migratory capacity (Figure 4c ). In addition, Boyden Chamber invasion assays using similarly transfected cells revealed that cell overexpressing DRIP-130 and Sp1-modulated anti-invasive behavior comparable to KiSS-1-transfected cells (Figure 4g ). These functional assays suggest that re-introducing DRIP-130 and Sp1 into highly metastatic melanoma cells results in reduced invasive and migratory behavior similar to the effect produced upon KiSS-1 overexpression.
Discussion
KiSS-1 expression is commonly lost during the progression of multiple forms of cancer, and the degree to which it is lost has become a relatively accurate indicator of the severity of tumor metastasis (Lee and Welch, 1997a; Kotani et al., 2001; Sanchez-Carbayo et al., 2003; Ikeguchi et al., 2004; Masui et al., 2004) . Re-introduction of KiSS-1 in highly metastatic cells which have progressively lost KiSS-1 expression, results in less migration and invasion and reduced metastasis (Lee and Welch, 1997b; Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001; Stafford et al., 2002) . Considering the importance of KiSS-1 expression in gauging metastasis, an understanding of the transcriptional regulation of KiSS-1 and the mechanisms whereby it is lost during the progression of cancer is essential. Here we demonstrate that KiSS-1 transactivation is controlled by the Sp1 co-activator complex DRIP-130 (Mitchell et al., 2006) . Specifically, loss of DRIP-130, one of 15 subunits which collectively forms the CRSP co-activator, leads to the loss of KiSS-1 transcriptional activation in metastatic melanoma cells (Taatjes and Tjian, 2004) . DRIP-130 was originally identified along with the other subunits of CRSP as being essential for Sp1-mediated gene transcription . In addition, other labs have found a correlation between loss of DRIP-130 and loss of KiSS-1 expression, although the exact mechanism behind this correlation has not been determined (Goldberg et al., 2003) . The region encoding DRIP-130, 6q16.3-q23, is commonly lost during progression of melanoma. In addition, this same region of chromosome 6 encodes activator protein (AP)-2a´, the expression of which has previously been shown to regulate transcription of KiSS-1 in breast cancer, suggesting that loss of this region of the genome is a key milestone in the loss of KiSS-1 expression and heightened metastasis (Goldberg et al., 2003; Mitchell et al., 2006) Although the GC-rich KiSS-1 promoter contains multiple Sp1 sites, serial truncations and targeted deletion of the first 100 bases of the KiSS-1 promoter revealed that this site mediated DRIP-130/Sp1 transcriptional regulation (Figures 1a and 3a) . The ability of both a Sp1-specific antibody to supershift the discrete 34-bp region of the KiSS-1 promoter in EMSA indicated that this element may modulate Sp1 , respectively) and compared to the vector-transfected negative control with little or no significant difference (a). Likewise, melanoma cells were co-transfected with Sp1 and DRIP-130 (e) and showed significant inhibition of cell migration as compared to the negative control (a). Wound-healing assays were also done on KiSS-1 expressing cells as a positive control (b). A typical wound seen after washing with phosphate-buffered saline before overnight incubation (f). (g) Results from Boyden chamber migration assays demonstrate that co-transfection of Sp1 and DRIP-130 leads to significant migratory inhibition compared to single transfections, similar to the inhibitory effect of KiSS-1 overexpression in the cells. transactivation through action of DRIP-130. Sp1 and DRIP-130 were also found capable of forming a complex with the KiSS-1 promoter using ChIP (Figure  3c and d) . Although targeted mutations of the overlapping Sp1 sites were attempted, owing to the high GCcontent, we found that generation of 100-bp constructs bearing such mutations to the KiSS-1 promoter was not feasible, therefore we are unable to determine which Sp1 elements, or whether all elements in the 34 bp Sp1 cluster are essential for Sp1-mediated transcriptional control.
The data presented here, as well as data from previous publications, indicates the importance of chromosome 6 (6q16.3-q23) in maintaining KiSS-1 expression (Goldberg et al., 2003; Mitchell et al., 2006) . Additionally, it suggests a possible mechanism for loss of KiSS-1 during the progression of metastatic melanoma, by which loss of 6q16.3-q23 which encodes DRIP-130 leads to reduced KiSS-1 expression in metastatic melanoma ( Figure 5 ). In normal cells, DRIP-130 is expressed properly and interacts with other proteins in the CRSP complex that helps form the larger mediator complex, which regulates Sp1-mediated transcriptional regulation (Figure 5a ). Mutation or loss of the region encoding DRIP-130 results in reduced KiSS-1 expression through failure of proper CRSP and mediator complex formation (Figure 5b) , resulting in the loss of metastatic inhibition seen in metastatic melanoma lacking KiSS-1 expression. Although DRIP-130 may be simultaneously activating other genes, thus indirectly impacting KiSS-1 expression, the necessity of the mediator complex (containing DRIP-130) for Sp1-modulated transactivation supports the direct influence of DRIP-130 levels on KiSS-1 transcription.
Sp1 regulates multiple genes expressed in both normal and tumorigenic tissues (Lania et al., 1997; Suske, 1999; Black et al., 2001; Safe and Abdelrahim, 2005) . Genes involved in cell cycle progression, cell growth and differentiation, apoptosis and capillary growth have all been shown to contain GC-rich Sp1 elements (Ryuto et al., 1996; Finkenzeller et al., 1997; Ji et al., 1997; Dong et al., 1999) . Recent studies indicate Sp1 expression is directly correlated to severity of multiple forms of cancer, suggesting that Sp1 expression may also be a determining factor in tumor metastatic progression (Shi et al., 2001; Zhu et al., 2002; Wang et al., 2003; Abdelrahim et al., 2004; Jiang et al., 2004; Yao et al., 2004; Liu et al., 2005; Wang and Bannon, 2005) . Another explanation for increased Sp1 in such cases, however, is that the normal ratio of Sp1 expression is altered such as in the overexpression of thrombin receptor protease-activated receptor (PAR-1). Tellez et al. (2003) explains how an irregular ratio of AP-2a´/ Sp1 in which AP-2 is lost leads to the heightened expression of PAR-1. Considering that Sp1 levels remain relatively constant in both normal and metastatic melanoma (Figure 2 ), a similar mechanism by which the DRIP-130/Sp1 ratio is reduced may likewise account for the loss of key genes in tumor metastasis suppression, such as KiSS-1, and result in increased tumor metastasis.
Our data supports previous studies suggesting a correlation between loss of KiSS-1 expression and loss of DRIP-130 in metastatic melanoma cells and, in the course of our studies, we have localized the responsive region of the promoter to within 34-bp of KiSS-1 promoter. Considering the growing clinical importance of KiSS-1 as an effective suppressor of metastasis, our studies suggest a mechanism for its regulation in normal tissues and offer a likely mechanism for its loss during progression of cancer metastasis.
Methods and materials
Chemicals and constructs [g-32 P]adenosine triphosphate (300 Ci/mmol) was obtained from PerkinElmer Life Sciences (Wellesley, MA, USA). Poly(dI-dC) and T4 polynucleotide kinase were purchased from Roche Molecular Biochemicals (Indianapolis, IN, USA). Antibodies for DRIP-130, Sp1, IgG and actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Luciferase reagent and lysis buffer were obtained from Promega Corp. (Madison, WI, USA). The KiSS-1 promoter was cloned as described previously (Mitchell et al., 2006) . Sp1 was Regulation of KiSS-1 expression in melanoma by Sp1 and DRIP-130 DC Mitchell et al cloned as described previously (Tellez et al., 2003) . The DRIP-130 construct was provided by Dr Jun Qin (Baylor, Houston, TX, USA).
Cell culture and transfection Dulbecco's modified Eagle's medium (DMEM) with phenol red, 100 Â antibiotics and fetal bovine serum (FBS) were purchased from HyClone (Logan, UT, USA). Media was supplemented with Hepes Buffer (Hyclone; Logan, UT, USA) and 100 Â minimum essential medium non-essential amino acids (Gibco; Grand Island, NY, USA). T47D and MDA-435 were obtained from the American Type Culture Collection (Manassas, VA, USA). Breast cell lines were maintained as described previously (Mitchell et al., 2006) . Transfection of melanoma cell lines was carried out according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). In brief, DNA was added, using a Lipofectamine to DNA ratio of 2:1 in each well for 6 h. Empty vector was used to normalize DNA concentrations.
Luciferase assay
Upon reaching B60% confluence, reporter gene constructs were transfected. Cells were harvested after 48 h, and luciferase activity and b-galactosidase levels were then measured as previously published (Mitchell et al., 2006) .
Western immunoblot analysis
Melanoma cell lines (2.0 Â 10 7 ) were seeded in 100-mm petri dishes and incubated overnight. Lysates were harvested and protein concentrations determined as previously published (Mitchell et al., 2006) . Ten microgram of each sample was then heat denatured, and loaded onto either 10 or 15% sodium dodecylsulfate-polyacrylamide gel electrophoresis gels, as needed. Following transfer to nitrocellulose (Pall Corp., Pensacola, FL, USA), membranes were blocked, and primary (1:1000) and secondary (1:10 000) antibodies were added. Proteins were detected using the SuperSignal West Pico Chemiluminescent substrate (Pierce, Milwaukee, WI, USA) according to the manufacturer's instructions.
EMSA
Nuclear extracts from A375SM and WM2664 cells were harvested as described previously (Abdelrahim et al., 2004) . KiSS-1 promoter-derived oligonucleotides were annealed, 5 0 -end labeled, and EMSA was carried out as described previously (Mitchell et al., 2006) . DNAprotein complexes were then resolved on 5% PAGE gel. Antibody-protein complexes were observed as supershifted or immunodepleted complexes.
ChIP assay
ChIP was performed using A375SM and WM2664 cells transfected with both DRIP-130 and Sp1 as described previously (Mitchell et al., 2006) . Precleared supernatant was incubated with antibodies to IgG, DRIP-130 and Sp1 overnight at 41C. The region between À1 and À156 of the KiSS-1 promoter was amplified from the immunoprecipitated chromatin using the following primers: sense, 5 0 -TTCTCCCCAGCTCCCTGAT-CA CATCC-3 0 and antisense, 5 0 -CTGCCTCCAGT-CACA GAGC-3 0 . The B150-bp PCR product was resolved on a 2.5% agarose gel and visualized under ultraviolet light.
Semiquantitative RT-PCR analysis Total RNA was harvested using TRIzol (Invitrogen). First-strand complementary DNA synthesis was performed using Moloney murine leukemia virus reverse transcriptase and oligo-dT (Promega) according to the manufacturer's protocol. Primer sequences used for detection of KiSS-1 transcripts were 5 0 -GCCCACCAT GA-ACTCACTG-3 0 and 5 0 -CTGC-CCCGCACCTG CG-3 0 . Amplified products were B400 bases in length. Additionally, primers for b-actin were 5 0 -GGCTCCG GCATGTGCAAGGC-3 0 and 5 0 -AGATTTTCTCCAT GTCGTCC-3 0 , which resulted in PCR products of B200 bases. Optimal PCR cycles required for linear amplification was determined for each (b-actin required 21-23, KiSS-1 required 24-28 cycles). PCR products were separated on 2% agarose gels, and quantitated using Alpha Imager software (Alpha Innotech, San Leandro, CA, USA).
Invasion and migration assays A375SM and WM2664 melanoma cell lines were transiently transfected with DRIP-130, Sp1 or vector alone. Transfection efficiency was determined visually upon transfection of a green fluorescent protein-tagged vector. Cell migration assays were carried out in modified Boyden chambers (Banyard et al., 2000; Stafford et al., 2002) . Filters were incubated with DMEM þ bovine serum albumin after coating them in collagen for 1 h. Filters were then put into DMEM without FBS and with 0.5 ng of mouse basic fibroblast growth factor (bFGF). Cells were seeded at approximately 20 000 cells/well on top of the filter and incubated 18 h. Cells were washed, fixed, stained and counted as previously published (Banyard et al., 2000; Stafford et al., 2002) Additionally, scratch assays were carried out on Sp1/DRIP-130 co-transfected A375SM and WM2664 cells. Cells were allowed to grow to confluency in collagen-coated plates, scratched and incubated in fresh DMEM with 0.5 ng of mouse bFGF. Pictures were taken after 24 h using a Nikon digital camera.
